%0 Journal Article
%T 局部晚期食管癌的新辅助治疗模式<br>Neoadjuvant Treatment Modality for Locally Advanced Esophageal Cancer
%A 王政宏
%A 朱冰
%J Advances in Clinical Medicine
%P 7095-7102
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.135991
%X 我国是世界范围内的食管癌高发区域，由于缺乏早期的特异性症状，很多食管癌确诊时已发展为局部晚期。新辅助放化疗的出现为局部晚期食管癌患者提供了继单纯手术后又一治疗选择，虽然经历了褒贬不一的看法，但目前国内外大多数研究认为新辅助放化疗能有效增加食管癌的远期生存率及无病生存率，并提高了手术R0切除率、病理缓解率，因此逐渐成为局部晚期食管癌的标准化治疗方案。近年来免疫治疗及靶向治疗也开始加入食管癌新辅助治疗的队列中。本文就局部晚期食管癌的新辅助治疗方式进行综述。<br />
China is a region with a high incidence of esophageal cancer worldwide, and due to the lack of early specific symptoms, many esophageal cancers have developed into locally advanced stages when di-agnosed. The emergence of neoadjuvant chemoradiotherapy provides another treatment option for patients with locally advanced esophageal cancer after surgery alone. Although it has experienced mixed opinions, most studies at home and abroad now believe that neoadjuvant chemoradiothera-py can effectively increase the long-term survival rate and disease-free survival rate of esophageal cancer, and improve the surgical R0 resection rate and pathological remission rate, so it is gradually becoming a standardized treatment option for locally advanced esophageal cancer. In recent years, immunotherapy and targeted therapy have also started to join the queue of neoadjuvant treatment for esophageal cancer. This article reviews the neoadjuvant treatment modalities for locally ad-vanced esophageal cancer.
%K 局部晚期食管癌，新辅助治疗，R0切除，病理缓解<br>Locally Advanced Esophageal Cancer
%K Neoadjuvant Therapy
%K R0 Resection
%K Pathological Remission
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64981